Sandoz voluntarily recalls 24 lots of injectable methotrexate

10/27/2010 | Reuters

Novartis' Sandoz unit is recalling 24 lots of methotrexate, an injectable chemotherapy drug, after discovering glass particulates in the product. The recall affects vials of 50 milligrams per 2 milliliters and 250 milligrams per 10 milliliters. Sandoz has not received reports of adverse effects concerning the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Chief Medical Officer
Meritus
Tempe, AZ
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX